Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Whats next Glucagon-like peptide 1 (GLP-1) agonists, used to treat Type 2 diabetes and obesity, have been a success story in the industry, with Novo Nordisk riding a blockbuster wave with Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity, and Eli Lilly and Company also riding the wave with Mounjaro/Zepbound (tirzepatide), a dual-activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 medication, respectively for treating Type 2 diabetes and obesity
Alternatively, OPA1 and SNX9 regulate the loading of mitochondrial cargo into extracellular vesicle routes (126), while a distinct pathway involving the E3 ligase MARCH5 and PEX3 generates pre-peroxisomal carriers (70)
Fueled by the FDAs approval of Wegovy for weight loss in 2021, prescriptions for GLP-1 (glucagon-like peptide-1) drugs rose 587% from 2019 to 2024 as usage expanded beyond diabetes management
'We ask everyone to report any suspected side effects using our Yellow Card scheme website
